Clinical Research Directory

Inclusion Criteria: * Age ≥18 on day signing informed consent * Histologically or cytologically confirmed cancer. * Performance status of 0-2 on the ECOG Performance Scale. * Advanced or locally advanced disease, not eligible for curative-intent treatment. * Life expectancy \> 6 months. * At least one measurable non-brain site of disease with a diameter ≥ 4.5 cm, in any direction * Ability to understand and willingness to sign the written informed consent document (or that of legally authorized representative, if applicable). Reproductive Status * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of LRT. * Women must not be breastfeeding. * WOCBP must agree to follow instructions for method(s) of contraception for the duration of LRT plus 30 days (duration of ovulatory cycle). * Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of LRT plus 90 days (duration of sperm turnover). * Investigators shall counsel WOCBP patients and male patients who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Exclusion Criteria: * Additional malignancy that is progressing or requires active treatment. Exceptions include basal and squamous cell carcinoma of the skin or in situ cervical * Currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the start of LRT. * Prior high-dose radiotherapy overlapping with any planned site of protocol radiotherapy, if the dose overlap is \> 10 Gy or is determined not safe by the treating physician. * HIV patients with CD4+ T-cell counts \< 350 cells/mcL or with a history of AIDS-defining opportunistic infection, within the 12 months prior to registration